The Climate for Investing in Platform Technologies
This article was originally published in Start Up
The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.
You may also be interested in...
A short summary of recent clinical and market developments in the medical device industry.
An example of the looming power of synthetic biology, one of its first start-ups, Codon Devices, is providing researchers with hundreds of specified protein variants using automated, microarray-based fabrication methods. Its platform could help address pharma's productivity problem by decreasing the size of a discovery pipeline and shrinking the development timeline, and position the company to negotiate downstream payments for its efforts based on the success of clients' development programs.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.